Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Expert faculty discuss the latest data on using SGLT2 inhibitors to reduce HF risk in patients with T2D
Jennifer B. Green, MD
Mikhail N. Kosiborod, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.16 MB
Released: June 7, 2021

Acknowledgements

Provided by the Endocrine Society

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by an independent educational grant from
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company

Related Content

Dr Jennifer Green on why to be vigilant in assessing for HF in patients with T2D, and the evolving use of SGLT2 inhibitors in these patients, from Clinical Care Options (CCO)

Jennifer B. Green, MD Released: June 22, 2021

Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM

Veronica K. Piziak, MD, PhD, FACP
Program Director
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: January 11, 2019 Expired: No longer available for credit

Type 2 diabetes management: Dr. Veronica K. Piziak on NPH, regular insulin, switching to avoid hypoglycemia/reduce CV risk in T2DM

Veronica K. Piziak, MD, PhD, FACP
Program Director
Released: December 10, 2018

T2DM and CV risk management. Guillermo Umpierrez on choosing A1C and using guidelines/algorithms for metformin, SUs, TZDs, DPP-4s, SGLT2s

Guillermo E. Umpierrez, MD, CDE Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Released: December 5, 2018 Expired: No longer available for credit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue